Sign inJoin free

Watch / Company News

Recce on track to tackle Indonesia's obesity crisis

11 Dec 20245:12

Recce on track to tackle Indonesia's obesity crisis

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

James Graham, CEO of Recce Pharmaceuticals (ASX:RCE) shares that the company is advancing its antibiotic treatments for diabetic foot infections. Recce (ASX:RCE) has received approval for a phase three clinical trial in Indonesia, targeting a population of 280 million, 11% of which have diabetes. James sees this as a gateway to the ASEAN markets, reaching 700 million people, presenting significant commercial opportunities.


James states that the trials have shown promising results, with 100% of phase two participants responding positively. The Indonesian and Australian governments support Recce's efforts, recognising the antibiotic as the first new class in over 40 years. Financial benefits include a 43.5% R&D rebate on a $2 million study cost, aiding production and market access.

Recce (ASX:RCE) aims for broad-spectrum applications, moving towards phase three studies focused on the US, FDA, and Europe. James envisions two product tiers: a premium one aligning with FDA standards and a cost-effective option for broader markets, including the Middle East, India, and potentially the UK post-Brexit. Commercialisation is expected within 18 months.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy